New York, Feb 7, 2026, 11:29 ET — The market has shut for the day.
- AbbVie shares closed out Friday on a positive note, capping a choppy week as investors parsed earnings and eyed drug-sales numbers.
- Investors continue to size up Skyrizi and Rinvoq’s growth, eyeing how those numbers stack up against intensifying competition.
- Focus stays on the coming week after a recent credit-rating action and a new regulatory filing.
AbbVie finished Friday’s session 2% higher at $223.43, notching a second day in the green while U.S. equities climbed. The stock remains about 9% shy of its 52-week high. Trading volume landed slightly below its recent average. 1
Shares are rebounding as investors digest AbbVie’s latest numbers and look ahead to 2026. The company reported fourth-quarter net revenue up 10% to $16.618 billion, with adjusted earnings per share—excluding certain items—at $2.71. For 2026, AbbVie projected adjusted EPS between $14.37 and $14.57. CEO Robert Michael called for “another year of robust growth in 2026.” 2
Still, that outlook wasn’t enough to keep sellers at bay. Shares tumbled almost 6% on Wednesday after Rinvoq posted sales just shy of what the Street wanted. Analysts pointed to rising pressure from rivals in immunology, calling out Johnson & Johnson’s Tremfya in inflammatory bowel disease as a growing threat. “Investors continue to have concerns about growing competition,” said William Blair analyst Matt Phipps. AbbVie CFO Scott Reents said the firm is bracing for “low-single-digit” pricing headwinds for Skyrizi and Rinvoq. 3
Moody’s Ratings bumped AbbVie up to A2 from A3 on Friday, shifting its outlook to stable. The agency pointed to strong performance in core immunology and neuroscience. Still, Moody’s highlighted AbbVie’s significant reliance on immunology drugs and its heavier vulnerability to U.S. drug-pricing changes versus some rivals. 4
Pipeline news is moving too. AbbVie has filed for approval with both the U.S. Food and Drug Administration and the European Medicines Agency for Rinvoq, targeting adults and adolescents with non-segmental vitiligo, using data from Phase 3 trials to support the applications. “Many patients experience ongoing frustration” over the limited systemic treatments available, according to Kori Wallace, AbbVie’s immunology executive. 5
Analysts pointed to Humira as the real standout this quarter. David Risinger at Leerink Partners attributed most of the revenue beat to the aging blockbuster. Cantor Fitzgerald’s Carter Gould called the 2026 earnings outlook a positive, but flagged that investors are zeroed in on revenue details and product forecasts—Skyrizi in particular. 6
During the earnings call, AbbVie executives emphasized their aggressive stance in inflammatory bowel disease. Chief commercial officer Jeffrey Stewart told analysts the company’s “compete level is extremely high,” noting that despite fresh competition entering the field and physicians considering new therapies, AbbVie isn’t backing down. 7
The market remains closed until Monday, leaving traders to wonder if Friday’s bounce will stick or slip away once trading resumes. Focus shifts to any updates on price targets and the latest channel checks, as investors look for signs that management’s upbeat outlook for Skyrizi and Rinvoq demand is on solid ground.
Still, policy risk hasn’t gone away. The Centers for Medicare & Medicaid Services listed both Botox and Botox Cosmetic among the drugs selected for the third round of Medicare price talks, with any final prices set for Jan. 1, 2028. Drugmakers have until Feb. 28, 2026, to opt in or out. 8
AbbVie’s immediate focus remains on post-earnings moves—specifically, how Skyrizi and Rinvoq stack up against rivals, plus whether the path forward for the vitiligo filing gets any clearer. Investors have their eyes on Feb. 28 as the next key date.
